camostat has been researched along with Cancer of Mouth in 3 studies
camostat : A benzoate ester resulting from the formal condensation of the carboxy group of 4-guanidinobenzoic acid with the hydroxy group of 2-(dimethylamino)-2-oxoethyl (4-hydroxyphenyl)acetate. It is a potent inhibitor of the human transmembrane protease serine 2 (TMPRSS2) and its mesylate salt is currently under investigation for its effectiveness in COVID-19 patients.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, G | 1 |
| Sui, Y | 1 |
| Zhou, Y | 1 |
| Ya, J | 1 |
| Yuan, C | 1 |
| Jiang, L | 1 |
| Huang, M | 1 |
| Ohkoshi, M | 2 |
| Oka, T | 1 |
1 review available for camostat and Cancer of Mouth
| Article | Year |
|---|---|
[Protease inhibitors as anticancer chemotherapy--experimental and clinical studies].
Topics: Adenocarcinoma; Animals; Carcinoma, Lewis Lung; Carcinoma, Squamous Cell; Cell Division; Colonic Neo | 1995 |
2 other studies available for camostat and Cancer of Mouth
| Article | Year |
|---|---|
Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat.
Topics: Antiviral Agents; Carcinoma, Squamous Cell; COVID-19; COVID-19 Drug Treatment; Esters; Guanidines; H | 2021 |
Clinical experience with a protease inhibitor [N,N-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methanesulfate for prevention of recurrence of carcinoma of the mouth and in treatment of terminal carcinoma.
Topics: Adult; Carcinoma, Squamous Cell; Esters; Evaluation Studies as Topic; Female; Gabexate; Guanidines; | 1984 |